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Background/Aim. We evaluate the impact of combined pentoxifylline and high-dose vitamins E to standard antiviral treatment on
RBV-induced haemolytic anaemia. Patients and Methods. Selected 200 na¨ ıve chronic HCV patients, were randomized to receive
eitherthestandardantiviraltherapy (peginterferon α-2bandRBV)pluspentoxifylline(800mg)andhigh-dosevitaminE(1000iu)
daily (combined group) or received standard antiviral therapy plus placebo only (control group). They were followed up during
treatment course and for 6 months posttreatment to assess the occurrence of anaemia and virological response, respectively.
Results. RBV dose modiﬁcation due to anaemia were signiﬁcantly less in combined group (8.5 versus 21.5%. P<. 05).Withdrawal,
secondary to sever anemia (Hb < 8.5gm%), was recorded only in 6 (28.6%) patients of the control group. Both (ETR) and
(SVR) were signiﬁcantly higher in combined group than control group by both intention-to-treat analysis (71 versus 56%,
P<. 05 and 66 versus 49%, P<. 05) and per-protocol analysis (85.5 versus 70.9%, P<. 05 and 79.5 versus 62%, P<. 05).
Conclusion. Pentoxifylline and vitamin E can ameliorate RBV-associated haemolysis; improve compliance and virologic clearance
when combined with the standard antiviral therapy in patients with chronic hepatitis C.
1.Introduction
The hepatitis C virus (HCV) is a major public health
problem and a leading cause of chronic liver disease, with
approximately 3% of the world’s population aﬀected [1, 2].
Hepatitis C genotype 4 is the prevalent genotype in the
Middle East [3]. Its prevalence in Egypt is estimated to be
more than 90% of chronic hepatitis C patients [4].
Recently, ribavirin (RBV) has been used in combination
withpegylatedinterferon(IFN)asthemosteﬀectiveantiviral
therapy [5]. However, RBV-induced anaemia is the major
dose-limiting factor in the combined therapy of RBV and
IFN products [6].
Anaemia is likely related to extensive RBV accumulation
in erythrocytes subsequent to possible active unidirectional
transmembrane transport. RBV exerts its toxicity through
the inhibition of intracellular energy metabolism and oxida-
tive membrane damage, leading to an accelerated extravas-
cular hemolysis by the reticuloendothelial system [7].
Previous studies proved that the maintenance of high-
dose ribavirin by preventing haemolytic anaemia using high
supplementation doses of antioxidants, like vitamin E and
vitamin C, may lead to better sustained virological response
rate by pegylated IFN plus ribavirin therapy, indicating that
the dose of ribavirin is an important factor for eﬀective
combination therapy [8].
Pentoxifylline which is a trisubstituted xanthine deriva-
tive has been used successfully in the treatment of peripheral
arterial disease [9], diabetic nephropathy [10], diabetic
retinopathy [11], and coronary artery disease in diabetics
[11],generallyin allconditionsin which erythrocytestiﬀness
and increased blood viscosity are believed to play a role
[11]. Recently, it showed many advances in liver diseases
[12]. It has long been viewed as a potential antiﬁbrotic
agent [13], in addition to its modulating eﬀect on insulin
resistance through downregulation of TNF, it could be
a potential mechanism for improvement in patients with
nonalcoholic steatohepatitis (NASH) [12, 14, 15]. Our study2 International Journal of Hepatology
Table 1: Guidelines for dose modiﬁcation and discontinuation of PEG-Intron or PEG-Intron/Rebetol for Hematologic toxicity [16].
Laboratory values PEG PEG-Intron Rebetol
Hb∗
<10.0g/dL — Decrease by 200mg/day
<8.5g/dL Permanently discontinue Permanently discontinue
WBC
<1.5×109/L Reduce dose by 50% —
<1.0×109/L Permanently discontinue Permanently discontinue
Neutrophil
<0.75×109/L Reduce dose by 50% —
<0.5×109/L Permanently discontinue Permanently discontinue
Platelets
<80×109/L Reduce dose by 50% —
<50×109/L Permanently discontinue Permanently discontinue
∗For patients with a history of stable cardiac disease receiving PEG-Intron in combination with ribavirin, the PEG-Intron dose should be reduced by half
and the ribavirin dose by 200mg/day if a >2g/dL decrease in haemoglobin is observed during any 4-week period. Both PEG-Intron and ribavirin should be
permanently discontinued if patients have haemoglobin levels <12g/dL after this ribavirin dose reduction.
Hb: haemoglobin
WBC: White blood cell.
aimed to evaluatethe impact of combined pentoxifylline and
high-dosevitaminEonthestandardtreatmentofHCVtotry
ameliorating ribavirin-induced anaemia, aiming to improve
treatment adherence and virological response.
2.PatientsandMethods
2.1. Patients’ Selection. This is a prospective, randomized,
single-blind, controlled study, carried out at the National
Liver Institute, Menouﬁya University, Sheben AL koom,
Egypt. The institute was established to provide specialized
care for patients with liver disease. The center receives
patients from almost all regions of Egypt, besides patients
from the neighbouring Arab countries.
BetweenJanuary and May2008,fourhundredandeleven
chronic hepatitis C patients presented to the outpatient
clinics, and they were examined and screened for the
eligibility of HCV treatment. They were CHC-genotype 4
Egyptian patients of either sex with age ranged from 18
to 50years and had detectable HCV RNA and liver biopsy
consistent with chronic hepatitis and signiﬁcant ﬁbrosis.
A total of 188 patients were excluded from the trial
because of concurrent infection with hepatitis B (38
patients), presence of hepatocellular carcinoma (8 patients),
decompensated cirrhosis (11 patients), history of psychi-
atric troubles (18 patients), presence of baseline anaemia
((Hb<13g/dL for men and <12g/dL for women)—39
patients), low absolute neutrophil count (ANC) <1500/mm3
(16 patients), and low baseline platelet count <75,000/mm3
(58 patients). An additional 23 patients declined to partici-
pate in the study.
Thisstudycomplieswiththestandards oftheDeclaration
of Helsinki and current ethical guidelines. After institutional
review board approval and written informed consent were
obtained, 200 subjects were recruited for the study. These
were randomly assigned into two equal groups with the aid
of a computer-generated table of random numbers.
2.2. Treatment Regimens. Each group received standard
antiviral therapy, includingp peginterferon α-2b ((1.5
mcg/kg/week) (Pegintern, Schering-Plough Co., Kenilworth,
NJ, USA)) plus ribavirin (Rebetol, Schering-Plough Co.,
Kenilworth, NJ, USA) in dose of 1000 or 1200mg/day
depending on patient weight if less or more than 75kg,
respectively. The duration of treatment was assigned for 48
weeks.
In the combined group, patients received high dose of
vitamin E (Vitamin E, Pharco Co., Egypt) in a dose of
1000IU/day plus pentoxifylline (Trental 400 SR, product of
Aventis Pharma, Germany) in a dose of 800mg/day orally,
in addition to standard antiviral therapy, while patients in
the other group received starch tablets (placebo) plus the
standard antiviral therapy, and they were considered as a
control group.Allmedicationswere suppliedbythe National
Liver Institute, Egypt.
2.3. Dose Modiﬁcation. Medications doses were modiﬁed
if haematological adverse events had occurred according
to the guidelines in Table 1 [16]. Growth factors such as
erythropoietin and granulocyte colony-stimulating factor
(G-CSF) were not given in this study except when patients
were beyond the dose modiﬁcation criteria, and those would
be ruled out from the study.
2.4. Followup and End Points. All subjects were monitored
during peginterferon-ribavirin treatment inbothgroupsand
for a further period of 24 weeks after the end of treatment.
They had biweekly outpatient visits during the ﬁrst month
and monthly visits during the rest of the treatment period as
well as during the 24-week follow-up period. At each visit,
a physical examination was performed, treatment and the
importance of treatment adherence were explained, adverse
eﬀects were recorded, and biochemical tests and blood
counts were performed. The eﬃcacy to standard antiviralInternational Journal of Hepatology 3
Table 2: Comparison of patient proﬁles and laboratory data in both groups.
Variable Group 1 (vit E and pentoxifylline) n:100 Group 2 (control) n:100 P value
Age (years) 44.3 ±12.34 5 .9 ±10.3N S
Sex M:F 69:31 58:42 NS
BMI kg/m2 26.8 ±5.72 7 .9 ±6.1N S
Peripheral blood cell count
Haemoglobin gm% 14.48 ±1.64 14.79 ±1.38 NS
Leukocyte (×103/mL) 6.64 ±1.85 6.67 ±1.9N S
Platelet (×103/mL) 198.73 ±62.4 192.21 ±76.32 NS
Blood biochemistry
AST (IU/L) 72.55 ± 46.82 73.19 ±39.47 NS
ALT (IU/L) 86.71 ±67.92 79.66 ±70.13 NS
Bilirubin (mg/dL) 0.91 ±0.62 1.02 ±0.66 NS
Creatinine (mg/dL) 1.13 ±0.42 0.99 ±0.38 NS
A.P. (IU/L) 124.3 ±54.82 132.02 ±64.7N S
Iron (mcg/dL) 82.7 ±60.78 5 .6 ±58.8N S
Ferritin ng/mL 132.7 ±42.8 129.64 ±39.24 NS
Liver Histology
F1-F2 68 62 NS
F3-F4 32 38
HCV-RNA PCR viral load iu/mL
<400,000iu/mL 66 58 NS
>400,000iu/mL 34 42
Ribavirin dosage
1000mg/day 38 29 NS
1200mg/day 62 71
NS: Non signiﬁcant (P>. 05).
therapy was deﬁned as undetectable HCV RNA level by PCR
at 12 weeks (early virological response EVR), at the end of
treatment (ETR), and after 24-week followup (SVR).
The primary end point of our study was to complete the
study protocol without major dose reduction due to anemia,
while secondary end pointswere the occurrence oftreatment
complicationnecessitating withdrawal or antiviral treatment
failure.
2.5. Statistical Analysis. Data was statistically analyzed using
SPSS(Statistical Package for Social Science)program version
17 for windows. Quantitative data were presented as mean
± SD. Qualitative data are presented as relative proportions.
Student t-test and the Mann-Whitney test were used to
compare’s means and medians for quantitative variables
where appropriate. The association between the categorical
variables was assessed by using the Chi-square test or Fisher
Exact test. P<. 05 was considered as statistically signiﬁcant.
3.Results
3.1. Basal Patients’ Proﬁle and Laboratory Data. Demo-
graphic features, laboratory, and histological staging in both
studied groups were presented in Table 2.T h e r ew a sn o
statistical diﬀerence between both groups as regards mean
age, sex ratio, mean body mass index, basal hematological
features, and blood chemistry.
As regards histological ﬁnding, there was no statistical
diﬀerence between patients with early ﬁbrosis (F1,F2) and
those with advancing ﬁbrosis (F3,F4) in both studied groups
(P>. 05). Also, there was no statistical diﬀerence as regards
the number of patients receiving initial ribavirin dosage
(either1000or1200mg/day)betweenbothgroups(P>. 05).
3.2.EﬃcacyandSafety. An umberofpatientswhocompleted
the study protocol (48ws) were comparable between both
studied groups (83% in combined group versus 79% in
control group, P>. 05) (Table 3). In combined group,
66 patients (79.5%) completed the protocol without dose
modiﬁcation of either peginterferon or ribavirin, while 7
patients (8.4%) needed ribavirin dose modiﬁcation due to
t h eo c c u r r e n c eo fm i l da n e m i a( H b<10gm, but >8.5gm%).
In addition, in 5 patients (6%) both drugs were reduced due
to combined anemia, neutropenia, and thrombocytopenia
(Table 3).
Seventeen patients (17%) in the combined group were
dropped out of the study; none of them had hematological
complications (Table 4). No complications related to either
vitamin E (heart failure, coagulopathy, and gastrointestinal
eﬀects) or pentoxifylline (cardiac arrhythmia, dizziness, and
gastrointestinal eﬀects)were recorded during study protocol,4 International Journal of Hepatology
Table 3: Course of antiviral treatments in studied groups.
Variable Combined group Control group
No and % of patients who completed the study protocol
With full dose of both drugs 66 54
Ribavirin reduction 7 17
Interferon reduction 5 4
Reduction of both drugs 5 4
No and % of patients who discontinued the study protocol
With dose reduction 17 21
Table 4: Causes of dropout from study protocols among studied groups.
Variable Combined group n:17 Control group n: 21 Signiﬁcance
Thyroiditis 2 2 NS
Autoimmune disease aggravation 2 1 NS
Skin eruption 3 1 NS
Depression or anxiety 3 2 NS
Fatigue 2 1 NS
Anaemia Hb <8.5gm% — 6 S
Neutropenia ANC <500/mm3 —3 S
Thrombocytopenia Platelet< 25 ×10/mm3 —2 N S
Retinal haemorrhage 1 — NS
Nephritic syndrome — 1 NS
Hearing disturbance 1 1 NS
Economical problems 3 1 NS
S: signiﬁcant (P<. 05)
NS: nonsigniﬁcant (P>. 05).
except some cases with mild ﬂushing and/or headache not
necessitating dose modiﬁcation or discontinuation.
In the control group, 54 patients (68.4%) completed
study protocol without dose modiﬁcation of both drugs,
while 17 patients (21.5%) needed ribavirin dose modiﬁca-
tion due to the occurrence of mild anemia, and another
4 patients (5%) needed reduction of both drugs due to
combined blood cytopenias.
Twenty-one patients (21%) in the control group were
dropped out of the study, with anemia as the cause of
discontinuation in 6 patients (28.6%) (Table 4). Patients
who were dropped out from hematological complications
in control group were ruled out of the study protocol with
receiving the appropriate treatment
3.3. Hematological Changes: (Figures 1, 2,a n d3). As regards
thechanges in hematological proﬁleduring treatment proto-
cols, combined group showed signiﬁcantly less reduction of
hemoglobin, leucocytes, and platelets if compared to control
group (P = .01, P = .009, and P = .01, resp.).
3.4. Virological Response. Both ETR and SVR were signif-
icantly higher in the combined group than those of the
control group by both intention to treat analysis (71 versus
56%—P<. 05 and 66 versus 49%, P<. 05) and per protocol
analysis (85.5 versus 70.9%, P<. 05 and 79.5 versus 62%,
P<. 05) (Table 5).
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Figure 1: Time course changes in mean leucocytic counts among
the studded groups showed signiﬁcant improvement in leucocytic
reduction in combined group during study protocol (P = .009).
4.Discussion
Inthisstudy,we elucidated,fortheﬁrst time, thatthecombi-
nation pentoxifylline and vitamin E signiﬁcantly ameliorates
the reduction of hemoglobin level during treatment with
peginterferon and ribavirin in chronic hepatitis C Egyptian
patients with signiﬁcant improvement in both ETR and SVR
rates in a randomized controlled trial.International Journal of Hepatology 5
Table 5: Comparison of diﬀerent virological responses between studied groups.
Response
Studied groups
Chi-square test P value Combined Control
Group 1 Group2
Intention to treat n:100 n:100
ETR 71 (71%) 56 (56%) 4.854 0.027∗
SVR 66 (66%) 49 (49%) 5.913 0.015∗
Per protocol n:83 n:79
ETR 71 (85.5%) 56 (70.9%) 5.133 0.023∗
SVR 66 (79.5%) 49 (62%) 6.014 0.014∗
ETR: end-of-treatment response.
SVR: sustained virological response.
∗signiﬁcant.
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Figure 2: Time course changes in mean haemoglobin percentage
among the studded groups showed signiﬁcant improvement in
haemoglobin reduction in combined group during study protocol
(P = .002).
Clinical evidence has shown the importance of ribavirin
in the treatment of CHC patients, butthis agent is associated
with frequent adverse events, necessitating dose reductions
and/ordiscontinuations[17].Ribavirinreductions,however,
can have a negative impact on SVR. Thus, the management
of ribavirin toxicity, especially anaemia, can allow patients to
continue full-dose combinationt h e r a p yw i t hp e g i n t e r f e r o n
and ribavirin, aiming for enhancing their probability of
attaining SVR [18].
Previous studies showed that vitamin E might pro-
tect red blood cell membranes from oxidative damage
due to ribavirin [19]. However, while many advocate the
potential beneﬁts of antioxidants, including vitamin E, on
ribavirin-induced haemolysis, no systematic studies have
been reported [20].
Based on previous reports of pentoxifylline in increasing
erythrocyte adenosine triphosphate levels and erythrocyte
deformability [21], and decreasing plasma ﬁbrinogen and
blood viscosity [21] which lead to reduction of both hemol-
ysis and pain crises in sickle cell disease [22], we assumed
that the combination of pentoxifylline and vitamin E may be
more eﬀective in ribavirin-induced haemolytic anaemia.
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Figure 3: Time course changes in mean platelet counts among the
studded groups showed signiﬁcant improvement in platelet count
reduction in combined group during study protocol (P = .01).
In our study, the addition of pentoxifylline and vitamin
E to peginterferon and ribavirin improved reduction in
haemoglobin, more signiﬁcantly than the other group who
took antiviral therapy plus placebo. This was similar to the
results of a previous work done by Kawaguchi et al., who
cleared that the addition of high doses of vitamin E and
vitamin C could prevent haemolytic anaemia during combi-
nation therapy with ribavirin and IFN α-2b in patients with
chronichepatitisC[19],whileSaeianetal.recommendedthe
addition of another water-soluble antioxidant, like N-acetyl
cysteine to vitamin E, aiming to enhance its antioxidant
protective eﬀect on erythrocyte membrane [20].
In ourstudy, the protective impact ofthe combined ther-
apy was seen through the reduction of both neutrophils and
platelet counts during treatment period which may point to
t h ee x t e n d e dp r o t e c t i v ee ﬀect of this combination to prevent
reticuloendothelial system (RES) destruction for diﬀerent
blood cells. It is suggested that pentoxifylline may increase
the ﬁlterability of diﬀerent blood cells while passing through
RES based on its proven role to increase ﬁlterability of red
blood cells and decrease adherence to endothelial cells [21].
A similar ﬁnding was reported by another group [19]
concerningtheprotectiveeﬀectofantioxidantslikevitaminE6 International Journal of Hepatology
and vitamin C on platelet counts. They attribute their results
just to antioxidant proprieties of the used vitamins.
The number of patients needed ribavirin dose reduction
w a ss i g n i ﬁ c a n t l yl e s si nt h ec o m b i n e dg r o u pw h i c hr e ﬂ e c t s
the protective role of adding pentoxifylline and vitamin
E to standard treatment of HCV. This improved patients’
compliance and adherence to treatment was associated with
signiﬁcant improvement of both ETR and SVR rates in
the combined group, which highlighted the beneﬁcial eﬀect
of this combination in increased compliance, maintained
high dose of ribavirin, and may be the inhibitory eﬀect of
pentoxifylline on several proinﬂammatory cytokines in the
liverlikeTNF-α[23],which might augmenttheantiviral role
of peginterferon and ribavirin.
Withdrawal from the study was comparable between
studied groups. Anemia was the most signiﬁcant cause of
withdrawal in control group, while no speciﬁc complication
related to either pentoxifylline or vitamin E was recorded.
This reﬂectsthesafety ofthiscombinationwhenaddedinthe
usedconditionstothestandardtreatmentofHCVduringthe
treatment protocol.
Previous reports denoted that administering erythro-
poietin can improve anaemia caused by peginterferon and
ribavirin therapy and is more eﬀective than dose reduction
at improving quality of life during treatment [24]. However,
erythropoietin, which is not approved by the US Food
and Drug Administration (FDA) for the use in patients
with HCV infection, adds another parenteral drug to the
patient’s treatment regimen and is associated with additional
costs, inconvenience, and potential side eﬀects [24], while
new suggested combination is safe and cost not more than
50dollar/treatment course for 48wees.
We concluded that adding both pentoxifylline and
vitamin E could ameliorate ribavirin-associated haemolysis,
improving compliance and virologic clearance with combi-
nation therapy with pegylated interferon and ribavirin in
patientswithchronichepatitisC.Thesuggestedcombination
was cheap, safe, and eﬀective and could replace the use of
more hazards and expensive erythropoietin in our studied
population, so worldwide use of this combination is recom-
mended to verify their eﬃcacy and safety in other genotypes
of HCV patients.
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